Lyell Immunopharma
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $2 | $6 | $15 | $8 |
Gross Profit | -2,330 | 6 | 15 | 8 |
EBITDA | -43,825 | -58,915 | -36,280 | -42,562 |
EBIT | -46,157 | -61,312 | -38,846 | -45,697 |
Net Income | -24,153 | -140,723 | -38,846 | -42,684 |
Net Change In Cash | 2 | 6 | 15 | 8 |
Free Cash Flow | -38,599 | -32,555 | -28,639 | -34,626 |
Cash | 90,770 | 60,181 | 123,575 | 98,804 |
Basic Shares | 21,876 | 17,093 | 18,268 | 14,793 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $36 | $61 | $130 | $84,683 |
Gross Profit | -11,503 | 61 | 130 | 84,683 |
EBITDA | -192,235 | -200,643 | -226,758 | -169,038 |
EBIT | -203,774 | -220,274 | -247,008 | -187,058 |
Net Income | -274,448 | -342,994 | -234,632 | -183,118 |
Net Change In Cash | 36 | 61 | 130 | 84,683 |
Free Cash Flow | -150,804 | -162,858 | -166,380 | -193,831 |
Cash | 60,181 | 105,597 | 145,647 | 123,554 |
Basic Shares | 17,093 | 13,074 | 12,549 | 12,354 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$1.10 |
2025-12-31 | -$7.68 |
2025-09-30 | -$2.13 |
2025-06-30 | -$2.89 |